The DEA's administrative process for moving marijuana from Schedule I to Schedule III under the Controlled Substances Act remains in the post-hearing phase following a June 29–July 15, 2026, proceeding before an administrative law judge. Partial rescheduling of state-licensed medical products and FDA-approved items occurred via a prior April 2026 order, while the broader rulemaking for remaining cannabis continues through required steps including proposed findings, briefs, an ALJ recommendation, exceptions, and a final DEA Administrator decision. Opponents participated exclusively in the hearing, and one key witness conceded statutory criteria for Schedule III were met. Litigation over any final rule is expected, extending timelines beyond historical rescheduling precedents. These procedural layers explain trader consensus pricing limited odds of full completion by December 31, 2026.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว$812,505 ปริมาณ
Dec 31, 2026
September 30
2%
December 31
23%
$812,505 ปริมาณ
September 30
$739 ปริมาณ
2%
December 31
$202,195 ปริมาณ
23%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA's administrative process for moving marijuana from Schedule I to Schedule III under the Controlled Substances Act remains in the post-hearing phase following a June 29–July 15, 2026, proceeding before an administrative law judge. Partial rescheduling of state-licensed medical products and FDA-approved items occurred via a prior April 2026 order, while the broader rulemaking for remaining cannabis continues through required steps including proposed findings, briefs, an ALJ recommendation, exceptions, and a final DEA Administrator decision. Opponents participated exclusively in the hearing, and one key witness conceded statutory criteria for Schedule III were met. Litigation over any final rule is expected, extending timelines beyond historical rescheduling precedents. These procedural layers explain trader consensus pricing limited odds of full completion by December 31, 2026.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ตลาดเปิดเมื่อ: Feb 7, 2026, 5:04 PM ET
ปริมาณการซื้อขาย
$812,505วันสิ้นสุด
Jan 1, 2027ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETผู้ตัดสินผล
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA's administrative process for moving marijuana from Schedule I to Schedule III under the Controlled Substances Act remains in the post-hearing phase following a June 29–July 15, 2026, proceeding before an administrative law judge. Partial rescheduling of state-licensed medical products and FDA-approved items occurred via a prior April 2026 order, while the broader rulemaking for remaining cannabis continues through required steps including proposed findings, briefs, an ALJ recommendation, exceptions, and a final DEA Administrator decision. Opponents participated exclusively in the hearing, and one key witness conceded statutory criteria for Schedule III were met. Litigation over any final rule is expected, extending timelines beyond historical rescheduling precedents. These procedural layers explain trader consensus pricing limited odds of full completion by December 31, 2026.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ปริมาณการซื้อขาย
$812,505วันสิ้นสุด
Jan 1, 2027ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETผู้ตัดสินผล
0x65070BE91...The DEA's administrative process for moving marijuana from Schedule I to Schedule III under the Controlled Substances Act remains in the post-hearing phase following a June 29–July 15, 2026, proceeding before an administrative law judge. Partial rescheduling of state-licensed medical products and FDA-approved items occurred via a prior April 2026 order, while the broader rulemaking for remaining cannabis continues through required steps including proposed findings, briefs, an ALJ recommendation, exceptions, and a final DEA Administrator decision. Opponents participated exclusively in the hearing, and one key witness conceded statutory criteria for Schedule III were met. Litigation over any final rule is expected, extending timelines beyond historical rescheduling precedents. These procedural layers explain trader consensus pricing limited odds of full completion by December 31, 2026.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย